20-216 - Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)Status: open
A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)
Treatment for Non-Small Cell Lung Cancer (NSCLC)
If you have questions about this trial or are interested in participating, please contact this Clinical Trial’s Coordinator by email at firstname.lastname@example.org.
This study is looking at how pembrolizumab (pembro for short) with chemotherapy and radiation followed by pembro plus olaparib (or placebo for olaparib) works compared to chemotherapy and radiation followed by durvalumab in treating NSCLC that cannot be treated surgically and has not metastasized outside the chest in patients who have not received prior treatment for their cancer.
Providers Associated With This Trial
- Robert Gilbert, M.D.Radiation OncologistAssistant Professor of Interdisciplinary Clinical Oncology
- Brian E. Persing, M.D.Medical Oncologist and HematologistDivision Director, Medical Oncology; Arlene and Mayer Mitchell Chair of Medical Oncology; Program Director, Medical Oncology Fellowship; Assistant Professor of Medical Oncology